150 related articles for article (PubMed ID: 34479769)
1. Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation.
Fundytus A; Wells JC; Sharma S; Hopman WM; Del Paggio JC; Gyawali B; Mukherji D; Hammad N; Pramesh CS; Aggarwal A; Sullivan R; Booth CM
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):28-35. PubMed ID: 34479769
[TBL] [Abstract][Full Text] [Related]
2. An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries.
Wells JC; Sharma S; Del Paggio JC; Hopman WM; Gyawali B; Mukherji D; Hammad N; Pramesh CS; Aggarwal A; Sullivan R; Booth CM
JAMA Oncol; 2021 Mar; 7(3):379-385. PubMed ID: 33507236
[TBL] [Abstract][Full Text] [Related]
3. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
Del Paggio JC; Berry JS; Hopman WM; Eisenhauer EA; Prasad V; Gyawali B; Booth CM
JAMA Oncol; 2021 May; 7(5):728-734. PubMed ID: 33764385
[TBL] [Abstract][Full Text] [Related]
4. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis.
Khan NA; Lombeida JI; Singh M; Spencer HJ; Torralba KD
Arthritis Rheum; 2012 Jul; 64(7):2059-67. PubMed ID: 22275179
[TBL] [Abstract][Full Text] [Related]
5. Questioning a publication bias between industry-funded and non-industry-funded randomized controlled trials on biological and small molecule therapy for rheumatoid arthritis.
Cohen N; Lavie RG; Manor Y; Mimouni M; Furst DE; Amarilyo G
Semin Arthritis Rheum; 2020 Feb; 50(1):7-11. PubMed ID: 31280935
[TBL] [Abstract][Full Text] [Related]
6. Impact of industry collaboration on randomised controlled trials in oncology.
Linker A; Yang A; Roper N; Whitaker E; Korenstein D
Eur J Cancer; 2017 Feb; 72():71-77. PubMed ID: 28027518
[TBL] [Abstract][Full Text] [Related]
7. Sample size and number of outcome measures of veterinary randomised controlled trials of pharmaceutical interventions funded by different sources, a cross-sectional study.
Wareham KJ; Hyde RM; Grindlay D; Brennan ML; Dean RS
BMC Vet Res; 2017 Oct; 13(1):295. PubMed ID: 28978314
[TBL] [Abstract][Full Text] [Related]
8. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
Del Paggio JC; Azariah B; Sullivan R; Hopman WM; James FV; Roshni S; Tannock IF; Booth CM
Ann Oncol; 2017 Jan; 28(1):157-162. PubMed ID: 27742650
[TBL] [Abstract][Full Text] [Related]
9. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review.
Sun X; Briel M; Busse JW; You JJ; Akl EA; Mejza F; Bala MM; Bassler D; Mertz D; Diaz-Granados N; Vandvik PO; Malaga G; Srinathan SK; Dahm P; Johnston BC; Alonso-Coello P; Hassouneh B; Truong J; Dattani ND; Walter SD; Heels-Ansdell D; Bhatnagar N; Altman DG; Guyatt GH
BMJ; 2011 Mar; 342():d1569. PubMed ID: 21444636
[TBL] [Abstract][Full Text] [Related]
10. An Audit of Interim Analyses of Randomized Controlled Trials (RCTs) Published in Three High Impact Factor Medical Journals Over a Seven- year Period (2012-2018).
Bose D; Ravi R; Gogtay N; Thatte UM; Borse T
Rev Recent Clin Trials; 2021; 16(4):403-408. PubMed ID: 34259150
[TBL] [Abstract][Full Text] [Related]
11. Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication.
Liang F; Zhu J; Mo M; Zhou CM; Jia HX; Xie L; Zheng Y; Zhang S
Ann Oncol; 2018 Oct; 29(10):2129-2134. PubMed ID: 30084933
[TBL] [Abstract][Full Text] [Related]
12. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.
Roseman M; Milette K; Bero LA; Coyne JC; Lexchin J; Turner EH; Thombs BD
JAMA; 2011 Mar; 305(10):1008-17. PubMed ID: 21386079
[TBL] [Abstract][Full Text] [Related]
13. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.
Addeo A; Weiss GJ; Gyawali B
JAMA Netw Open; 2019 May; 2(5):e193684. PubMed ID: 31074821
[TBL] [Abstract][Full Text] [Related]
14. Is funding source related to study reporting quality in obesity or nutrition randomized control trials in top-tier medical journals?
Kaiser KA; Cofield SS; Fontaine KR; Glasser SP; Thabane L; Chu R; Ambrale S; Dwary AD; Kumar A; Nayyar G; Affuso O; Beasley M; Allison DB
Int J Obes (Lond); 2012 Jul; 36(7):977-81. PubMed ID: 22064159
[TBL] [Abstract][Full Text] [Related]
15. Financial conflicts of interest and their association with outcome and quality of fibromyalgia drug therapy randomized controlled trials.
Pang WK; Yeter KC; Torralba KD; Spencer HJ; Khan NA
Int J Rheum Dis; 2015 Jul; 18(6):606-15. PubMed ID: 26012523
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Industry Funding on Randomized Controlled Trials of Biologic Therapies.
Gazendam AM; Slawaska-Eng D; Nucci N; Bhatt O; Ghert M
Medicines (Basel); 2022 Feb; 9(3):. PubMed ID: 35323717
[No Abstract] [Full Text] [Related]
17. Self-declared stock ownership and association with positive trial outcome in randomized controlled trials with binary outcomes published in general medical journals: a cross-sectional study.
Falk Delgado A; Falk Delgado A
Trials; 2017 Jul; 18(1):354. PubMed ID: 28747226
[TBL] [Abstract][Full Text] [Related]
18. Industry-funded versus non-profit-funded critical care research: a meta-epidemiological overview.
Janiaud P; Cristea IA; Ioannidis JPA
Intensive Care Med; 2018 Oct; 44(10):1613-1627. PubMed ID: 30151688
[TBL] [Abstract][Full Text] [Related]
19. The association of funding source on effect size in randomized controlled trials: 2013-2015 - a cross-sectional survey and meta-analysis.
Falk Delgado A; Falk Delgado A
Trials; 2017 Mar; 18(1):125. PubMed ID: 28292317
[TBL] [Abstract][Full Text] [Related]
20. Publication status of contemporary oncology randomised controlled trials worldwide.
Chen YP; Liu X; Lv JW; Li WF; Zhang Y; Guo Y; Lin AH; Sun Y; Mao YP; Ma J
Eur J Cancer; 2016 Oct; 66():17-25. PubMed ID: 27522246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
